Caitlin C Chrystoja1,2, Gail E Darling3, Nicholas E Diamant4, Paul P Kortan5, George A Tomlinson6,7, Wayne Deitel8, Audrey Laporte1, Julie Takata2, David R Urbach1,2,9. 1. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 2. Division of Support, Systems and Outcomes, University Healthy Network, Toronto, Ontario, Canada. 3. Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. 4. Division of Gastroenterology, Department of Medicine, University Health Network, Toronto, Ontario, Canada. 5. Division of Gastroenterology, Department of Medicine, St Michael's Hospital, Toronto, Ontario, Canada. 6. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 7. Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada. 8. Department of Medical Imaging, St Michael's Hospital and University of Toronto, Toronto, Ontario, Canada. 9. Department of Surgery, Women's College Hospital and University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVES: Achalasia is a chronic, progressive, and incurable esophageal motility disease. There is clinical uncertainty about which treatment should be recommended as first-line therapy. Our objective was to evaluate the effectiveness of pneumatic dilation compared with laparoscopic Heller myotomy with partial fundoplication in improving achalasia-specific quality of life. METHODS: This was a prospective, multicenter, randomized trial at five academic hospitals in Canada. Fifty previously untreated adults with a clinical diagnosis of primary achalasia, confirmed by manometric testing, were enrolled between November 2005 and March 2010, and followed for 5 years after treatment. Randomization was stratified by site, in random blocks of size four and with balanced allocation. Patients were treated with pneumatic dilation or laparoscopic Heller myotomy with partial fundoplication. The primary outcome was the difference between the treatments in the mean improvement of the achalasia severity questionnaire (ASQ) score at 1 year from baseline. Prespecified secondary outcomes included general and gastrointestinal quality of life, symptoms, esophageal physiology measures (lower esophageal sphincter relaxation and pressure, esophageal emptying, abnormal esophageal acid exposure), complications, and incidence of retreatment. Functional and imaging studies were performed blinded and all outcome assessors were blinded. RESULTS: There were no significant differences between treatments in the improvement of ASQ score at 1 year from baseline (27.5 points in the Heller myotomy arm vs. 20.2 points in the pneumatic dilation arm; difference 7.3 points, 95% confidence interval -4.7 to 19.3; P=0.23). There were no differences between treatments in improvement of symptoms, general and gastrointestinal quality of life, or measures of esophageal physiology. Improvements in ASQ score diminished over time for both interventions. At 5 years, there were no differences between treatments in improvement of ASQ score, symptoms, and general or gastrointestinal quality of life. There were no serious adverse events. No patient who received Heller myotomy required retreatment, whereas five patients treated initially with pneumatic dilation required retreatment. CONCLUSIONS: Treatment with pneumatic dilation or laparoscopic Heller myotomy similarly improves achalasia-specific disease severity at 1 year. Either of the therapeutic approaches can be used as first-line therapy for previously untreated adults with achalasia.
RCT Entities:
OBJECTIVES:Achalasia is a chronic, progressive, and incurable esophageal motility disease. There is clinical uncertainty about which treatment should be recommended as first-line therapy. Our objective was to evaluate the effectiveness of pneumatic dilation compared with laparoscopic Heller myotomy with partial fundoplication in improving achalasia-specific quality of life. METHODS: This was a prospective, multicenter, randomized trial at five academic hospitals in Canada. Fifty previously untreated adults with a clinical diagnosis of primary achalasia, confirmed by manometric testing, were enrolled between November 2005 and March 2010, and followed for 5 years after treatment. Randomization was stratified by site, in random blocks of size four and with balanced allocation. Patients were treated with pneumatic dilation or laparoscopic Heller myotomy with partial fundoplication. The primary outcome was the difference between the treatments in the mean improvement of the achalasia severity questionnaire (ASQ) score at 1 year from baseline. Prespecified secondary outcomes included general and gastrointestinal quality of life, symptoms, esophageal physiology measures (lower esophageal sphincter relaxation and pressure, esophageal emptying, abnormal esophageal acid exposure), complications, and incidence of retreatment. Functional and imaging studies were performed blinded and all outcome assessors were blinded. RESULTS: There were no significant differences between treatments in the improvement of ASQ score at 1 year from baseline (27.5 points in the Heller myotomy arm vs. 20.2 points in the pneumatic dilation arm; difference 7.3 points, 95% confidence interval -4.7 to 19.3; P=0.23). There were no differences between treatments in improvement of symptoms, general and gastrointestinal quality of life, or measures of esophageal physiology. Improvements in ASQ score diminished over time for both interventions. At 5 years, there were no differences between treatments in improvement of ASQ score, symptoms, and general or gastrointestinal quality of life. There were no serious adverse events. No patient who received Heller myotomy required retreatment, whereas five patients treated initially with pneumatic dilation required retreatment. CONCLUSIONS: Treatment with pneumatic dilation or laparoscopic Heller myotomy similarly improves achalasia-specific disease severity at 1 year. Either of the therapeutic approaches can be used as first-line therapy for previously untreated adults with achalasia.
Authors: H Inoue; H Minami; Y Kobayashi; Y Sato; M Kaga; M Suzuki; H Satodate; N Odaka; H Itoh; S Kudo Journal: Endoscopy Date: 2010-03-30 Impact factor: 10.093
Authors: Wout O Rohof; Renato Salvador; Vito Annese; Stanislas Bruley des Varannes; Stanislas Chaussade; Mario Costantini; J Ignasi Elizalde; Marianne Gaudric; André J Smout; Jan Tack; Olivier R Busch; Giovanni Zaninotto; Guy E Boeckxstaens Journal: Gastroenterology Date: 2012-12-28 Impact factor: 22.682
Authors: R Frankhuisen; R Heijkoop; M A van Herwaarden; D R de Vries; A J P M Smout; A Baron; M Samsom Journal: Dis Esophagus Date: 2008-04-22 Impact factor: 3.429
Authors: A A Borges; E M de O Lemme; L J Abrahao; D Madureira; M S Andrade; M Soldan; L Helman Journal: Dis Esophagus Date: 2013-04-02 Impact factor: 3.429
Authors: John E Pandolfino; Monika A Kwiatek; Thomas Nealis; William Bulsiewicz; Jennifer Post; Peter J Kahrilas Journal: Gastroenterology Date: 2008-07-22 Impact factor: 22.682
Authors: T H Taft; D A Carlson; J Triggs; J Craft; K Starkey; R Yadlapati; D Gregory; J E Pandolfino Journal: Neurogastroenterol Motil Date: 2018-01-08 Impact factor: 3.598
Authors: Anne P Ehlers; Brant K Oelschlager; Carlos A Pellegrini; Andrew S Wright; Michael D Saunders; David R Flum; Hao He; Farhood Farjah Journal: J Am Coll Surg Date: 2017-06-07 Impact factor: 6.113
Authors: Jocelyn de Heer; Madhav Desai; Guy Boeckxstaens; Giovanni Zaninotto; Karl-Hermann Fuchs; Prateek Sharma; Guido Schachschal; Oliver Mann; Thomas Rösch; Yuki Werner Journal: Surg Endosc Date: 2020-03-16 Impact factor: 4.584
Authors: R A B Oude Nijhuis; G Zaninotto; S Roman; G E Boeckxstaens; P Fockens; M W Langendam; A A Plumb; Ajpm Smout; E M Targarona; A S Trukhmanov; Blam Weusten; Albert J Bredenoord Journal: United European Gastroenterol J Date: 2020-02 Impact factor: 4.623